Drugs and Devices

FDA approves maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

On March 27, the U.S. Food and Drug Administration (FDA) approved Zejula (niraparib) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors responded completely or partially to platinum-based chemotherapy. Read more


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares